Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden

JAMA Oncol. 2019 Aug 22;5(11):1633-1635. doi: 10.1001/jamaoncol.2019.3221. Online ahead of print.

Abstract

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.